Velzatinib not checked
GSK · IDRX-42 · GSK6042981/IDRX-42
FollowEvery change as it happens, and a Monday email
Trials
8 active
8 in total · 3 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.”In the company’s words, NCT05489237 on ClinicalTrials.gov
- Tested for
- Gastrointestinal Neoplasms (7 trials), Gastrointestinal Stromal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
- Main trialPhase 3
- “The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria…”In the company’s words, NCT07218926 on ClinicalTrials.gov
- Other names
- IDRX-42 · GSK6042981/IDRX-42 · GSK6042981
Other drugs for Gastrointestinal Neoplasms
- DostarlimabGSK · Phase 3
- CAM2029Camurus AB · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
Coming up8
- 12 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
- 10 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 9 Sep 2027Phase 1 trial completes · ClinicalTrials.gov
- 29 Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- 25 Apr 2028Phase 1 trial completes · ClinicalTrials.gov
- 30 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Jan 2031Phase 2 trial completes · ClinicalTrials.gov
- 30 Aug 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 May 2028 | A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | |
| Phase 3Recruiting | 30 Aug 2032 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | |
| Phase 2Recruiting | 29 Nov 2027 | A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | |
| Phase 2Not yet recruiting | 31 Jan 2031 | A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) | |
| Phase 1Not yet recruiting | 12 Jan 2027 | A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants | |
| Phase 1Active, not recruiting | 10 Mar 2027 | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | |
| Phase 1Not yet recruiting | 9 Sep 2027 | A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib | |
| Phase 1Not yet recruiting | 25 Apr 2028 | A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026